UBS’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

UBS’s Portfolio EPRS Stock Details EPRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$8K	Buy	+1,120	New	+$9.7K	﹤0.01%	9129

Other funds holding EPRS

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Abingworth London, United Kingdom $304M AUM 95.02% 1-Year Est. Return

UBS's EPRS Position: Q3 2014 in Review

UBS opened a new position in EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2014: 1,120 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #9129 among its holdings.

21 funds tracked by Wall St. Rank hold EPRS as of Q3 2014.

UBS held 1,120 shares of EPIRUS BIOPHARMACEUTICALS INC COM worth $8K as of Q3 2014.
EPIRUS BIOPHARMACEUTICALS INC COM was a new UBS position in Q3 2014.
EPIRUS BIOPHARMACEUTICALS INC COM made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9129 holding.
21 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.